GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » YoY EPS Growth

Scopus BioPharma (Scopus BioPharma) YoY EPS Growth : 56.25% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Scopus BioPharma's YoY EPS Growth for the quarter that ended in Jun. 2023 was 56.25%.

Scopus BioPharma's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $-0.07.


Scopus BioPharma YoY EPS Growth Historical Data

The historical data trend for Scopus BioPharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma YoY EPS Growth Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EPS Growth
Get a 7-Day Free Trial - -291.30 -350.00 -92.59 64.74

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.51 -12.50 75.76 63.64 56.25

Scopus BioPharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Scopus BioPharma's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(-0.55--1.56)/ | -1.56 |
=64.74 %

Scopus BioPharma's YoY EPS Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EPS Growth (Q: Jun. 2023 )
=(Earnings per Share (Diluted) (Q: Jun. 2023 )-Earnings per Share (Diluted) (Q: Jun. 2022 )) / | Earnings per Share (Diluted) (Q: Jun. 2022 )) |
=(-0.07--0.16)/ | -0.16 |
=56.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scopus BioPharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Scopus BioPharma (Scopus BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein director, officer: Chairman 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager officer: See Remarks 1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson director, officer: Vice Chairman 71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Iv David Weild director 22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel director SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein director C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper director 7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka director, officer: President 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005

Scopus BioPharma (Scopus BioPharma) Headlines

From GuruFocus

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

By GlobeNewswire GlobeNewswire 10-08-2021